Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Dose Escalation And Expansion Study Of Pf-06801591 In Patients With Locally Advanced Or Metastatic Melanoma, Squamous Cell Head And Neck Cancer, Ovarian Cancer, Sarcoma, Non-small Cell Lung Cancer, Urothelial Carcinoma Or Other Solid Tumors

Trial Profile

A Phase 1, Open-label, Dose Escalation And Expansion Study Of Pf-06801591 In Patients With Locally Advanced Or Metastatic Melanoma, Squamous Cell Head And Neck Cancer, Ovarian Cancer, Sarcoma, Non-small Cell Lung Cancer, Urothelial Carcinoma Or Other Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sasanlimab (Primary) ; Sasanlimab (Primary)
  • Indications Adenocarcinoma; Endometrial cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Salivary gland cancer; Sarcoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 18 Mar 2022 Data from patients of this study were used to develop population PK model for sasanlimab, presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 25 Oct 2021 Results (n=38) assessing whether tumor responses of sasanlimab were associated with baseline TMB, PD-L1, CD8, and IFN gene signature levels, across multiple dose levels, routes of administration and broad range of tumor types from a cohort published in the Targeted Oncology
    • 15 Dec 2020 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top